SOURCE: Tulip BioMed, Inc.

December 05, 2006 08:28 ET

Tulip BioMed's Disposable Cannulas Used for Teaching Workshop at Saint Louis University

New Instruments Supporting Safer Cosmetic Surgery Used by Faculty in "Endoscopic and Minimally Invasive Surgery for the Aging Face" Workshop

SAN DIEGO, CA -- (MARKET WIRE) -- December 5, 2006 -- Tulip BioMed™, Inc. (PINKSHEETS: TPBD), a developer of medical devices and patented technologies for the living tissue markets, including plastic, cosmetic, and orthopedic surgeries, today announced it provided more than $2500 worth of disposable cannulas to Practical Anatomy & Surgical Education of Saint Louis University. The new disposable instruments were used in an intensive hands-on workshop entitled "Endoscopic and Minimally Invasive Surgery of the Aging Face," which took place Nov.17-18, 2006 at Practical Anatomy & Surgical Education. Minimally-invasive procedures are by far the fastest growing segment in the plastic and cosmetic markets according to statistics provided by the American Society of Plastic Surgeons.

This workshop was designed to provide plastic surgeons, facial plastic surgeons and cosmetic surgeons with an overview of contemporary surgical rejuvenation of the aging face, which includes fat transfer, and for which Tulip BioMed's instruments are specially designed. Tulip BioMed provided its disposable, minimally-invasive micro-cannulas for fat harvest, transfer and re-injection in a variety of sizes and tips. Special attention was directed toward restoring youthful volumes and contours to the aging midface, jawline, and neck. Approximately 35 participants and 17 faculty performed hands-on exercises on cadavers using state of the art techniques.

Oscar Ramirez, MD, FACS, who is a clinical assistant professor at Johns Hopkins University School of Medicine and the University of Maryland as well as a member of Tulip BioMed's Board of Scientific Advisors, was the featured speaker. According to Dr. Ramirez, the disposable cannulas have the potential to enhance fat graft survival. "When one studies the external surfaces, Tulip BioMed's disposable cannulas appear to create less micro-trauma. This implies reduced inflammatory irritation in a live patient, which may enhance results and reduce recovery times."

This workshop ran at the same time as several successful showings for Tulip BioMed at multiple fall medical conferences including: "Advances in Aesthetic Plastic Surgery: The Cutting Edge VI" in New York City, November 12 - 16; Annual Scientific Symposium of the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) held in Las Vegas, November 15 - 16; and QMP Aesthetic Surgery Symposium in Chicago, December 1 - 3. The new instruments were well-received by physicians who are concerned about patient safety and improved results.

The disposable instruments developed by Tulip BioMed are designed to solve cross-contamination issues by eliminating reuse of instruments in liposuction, fat transfer and other closed end cannula procedures. A lubricious coating, which covers both the inside and outside of the cannula, is designed to not only decrease the trauma to the cells inside the lumen, but also to increase the ease of manipulation for extraction and re-injection procedures, minimize bruising and shorten recovery periods.

Doctors who would like to sample Tulip BioMed instruments are encouraged to call the company at 800-978-8547.

About Tulip BioMed, Inc.

Tulip BioMed, Inc. (PINKSHEETS: TPBD) is a Nevada corporation with operations based in San Diego, California. Founded in 2004, Tulip BioMed, Inc. is a medical device, biotechnology company that manufactures and distributes patented technologies for the plastic and cosmetic surgery, biopsy, orthopedic surgery, stem cell therapy and other living tissue markets. Tulip BioMed, Inc. is the exclusive licensee of patented syringe connection devices that use the worldwide recognized Tulip brand name. Tulip BioMed, Inc. manufactures, markets, and distributes medical devices, adapted with these and other patented technologies, to physicians, clinics, military, health organizations, hospitals and other distribution outlets. For more information go to: Products are available for sale at

Safe Harbor: This press release contains certain forward-looking information about Tulip BioMed, Inc., which is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)," "feel(s)," "believe(s)," "will," "may," "anticipate(s)," and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, financial projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of Tulip BioMed, Inc., that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include: our lack of operating revenue and earnings history, our need for additional capital to pursue our business strategy. We are a non-reporting company and as such do not make periodic filings with the Securities and Exchange Commission. We trade on the Pink Sheets and there can be no assurances that a liquid market will develop in our securities. Readers are cautioned not to place undue reliance on these forward-looking statements. Tulip BioMed, Inc. does not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Contact Information

  • Contact:
    Beth Walsh
    Clearpoint Agency, Inc.
    Email Contact